Table 4.

Incidence (per 100 person-years) of serious adverse events in participants randomized to the intensive and standard treatment groups, by quintile of baseline DBP (N=9361)^*

	1st quintile		2nd quintile		3rd quintile		4th quintile		5th quintile
	< 68 mm Hg		68 – 74 mm Hg		75 – 80 mm Hg		81 – 87 mm Hg		≥ 88 mm Hg
	Intensive	Standard	Intensive	Standard	Intensive	Standard	Intensive	Standard	Intensive	Standard
Any serious adverse event	20.53	19.55	15.67	15.21	15.39	14.27	12.99	12.50	12.60	12.48
Serious adverse events associated with:
Hypotension	0.79	0.53	0.98	0.47	0.75	0.42	0.62	0.49	0.66	0.38
Syncope	0.98	0.65	0.70	0.70	0.93	0.59	0.66	0.52	0.46	0.32
Electrolyte abnormality	1.45	1.12	1.27	0.60	0.86	0.63	0.85	0.52	0.63	0.86
Acute kidney injury or acute kidney failure	1.83	1.34	1.45	0.63	1.55	0.59	0.88	0.81	1.10	0.73

^*The table presents incidence rates of the indicated adverse events expressed as number of events per 100 person-years of follow-up.

In corresponding Cox regression models with separate baseline hazards for each baseline DBP quintile, likelihood ratio tests comparing the hazard ratios for the intensive vs. standard SBP intervention between the 5 baseline DBP quintiles were non-significant (serious adverse event, interaction p = 0.98; hypotension, interaction p = 0.87; syncope interaction p = 0.83; electrolyte abnormality interaction p=0.13; acute kidney injury/ acute kidney failure, interaction p = 0.12).

DBP = diastolic blood pressure.